Zumbrennen-Bullough Kimberly B, Wu Qifang, Core Amanda B, Canali Susanna, Chen Wenjie, Theurl Igor, Meynard Delphine, Babitt Jodie L
From the Program in Anemia Signaling Research, Division of Nephrology, Program in Membrane Biology, Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114.
From the Program in Anemia Signaling Research, Division of Nephrology, Program in Membrane Biology, Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114
J Biol Chem. 2014 Aug 22;289(34):23796-808. doi: 10.1074/jbc.M114.577387. Epub 2014 Jul 7.
Systemic iron balance is controlled by the liver peptide hormone hepcidin, which is transcriptionally regulated by the bone morphogenetic protein (BMP)-SMAD pathway. In iron deficiency, liver BMP-SMAD signaling and hepcidin are suppressed as a compensatory mechanism to increase iron availability. MicroRNAs are small regulatory RNAs that have an increasingly recognized role in many biologic processes but are only recently implicated in iron homeostasis regulation. Here, we demonstrate that liver expression of the microRNA miR-130a is up-regulated by iron deficiency in mice. We identify the BMP6-SMAD signaling pathway as a functional target of miR-130a in hepatoma-derived Hep3B cells. Although the TGF-β/BMP common mediator SMAD4 was previously reported to be an miR-130a target to inhibit TGF-β signaling, we do not confirm SMAD4 as an miR-130a target in our biologic system. Instead, we determine that the BMP type I receptor ALK2 is a novel target of miR-130a and that miR-130a binds to two specific sites in the 3'-untranslated region to reduce ALK2 mRNA stability. Moreover, we show in mice that the increased liver miR-130a during iron deficiency is associated with reduced liver Alk2 mRNA levels. Finally, we demonstrate that down-regulation of ALK2 by miR-130a has a functional effect to inhibit BMP6-induced hepcidin transcription in Hep3B cells. Our data suggest that iron deficiency increases liver miR-130a, which, by targeting ALK2, may contribute to reduce BMP-SMAD signaling, suppress hepcidin synthesis, and thereby promote iron availability.
全身铁平衡由肝脏肽激素铁调素控制,铁调素受骨形态发生蛋白(BMP)-SMAD信号通路的转录调控。在缺铁状态下,肝脏BMP-SMAD信号传导和铁调素受到抑制,作为增加铁可用性的一种补偿机制。微小RNA是小的调节性RNA,在许多生物学过程中的作用日益受到认可,但最近才被认为参与铁稳态调节。在此,我们证明缺铁可使小鼠肝脏中微小RNA miR-130a的表达上调。我们确定BMP6-SMAD信号通路是肝癌来源的Hep3B细胞中miR-130a的功能靶点。尽管之前报道转化生长因子-β/骨形态发生蛋白共同介质SMAD4是miR-130a抑制转化生长因子-β信号传导的靶点,但在我们的生物学系统中,我们并未证实SMAD4是miR-130a的靶点。相反,我们确定骨形态发生蛋白I型受体ALK2是miR-130a的新靶点,且miR-130a与3'-非翻译区的两个特定位点结合以降低ALK2 mRNA的稳定性。此外,我们在小鼠中发现,缺铁期间肝脏中miR-130a增加与肝脏Alk2 mRNA水平降低有关。最后,我们证明miR-130a介导的ALK2下调对抑制Hep3B细胞中BMP6诱导的铁调素转录具有功能性作用。我们的数据表明,缺铁会增加肝脏miR-130a,其通过靶向ALK2,可能有助于减少BMP-SMAD信号传导、抑制铁调素合成,从而促进铁的可用性。